The following five articles of this special issue describe areas of particular clinical interest regarding ctDNA analysis. In the first of the series, Methylation analyses in liquid biopsy, Lissa and Robles review the exciting field of DNA methylation, which has emerged as a promising marker for detection, prognosis and follow-up of tumor dynamics. They summarize the investigational applications of methylated ctDNA in lung cancer, the technologies used and the challenges that befall the implementation of methylated ctDNA into the clinical setting. Taken all together, they foresee an increasing number of methylation-based biomarkers in lung cancer that will lead to the development of companion diagnostic kits on ctDNA, ready to be implemented in the routine clinical practice.
Next-generation sequencing (NGS), which allows to simultaneously detect multiple alterations in many genes, is revolutionizing genetic testing. Although initially developed to be used in nucleic acids derived from cells or tissues, many efforts are being devoted in order to make NGS possible in liquid-biopsy derived materials, particularly ctDNA. These efforts and the challenges ahead are reviewed by Malapelle et al. in the article Next Generation Sequencing techniques in liquid biopsy: focus on Non Small Cell Lung Cancer patients. Although liquid biopsy NGS requires a careful validation of the whole process including blood collection, ctDNA extraction, library preparation, sequencing and variant calling, the authors present evidence that NGS can be successfully applied to ctDNA analysis and has the potential to become a new gold standard technique for mutational testing in NSCLC patients.
Mutations in the EGFR gene are the most common druggable alterations in advanced NSCLC and they are used in the clinical setting to select patients for treatment with EGFR tyrosine kinase inhibitors (TKIs). In addition, detection of EGFR mutations in serial liquid biopsies can be extremely helpful to follow the course of the disease, as Mayo-de-Las-Casas et al. describe in their article Usefulness of circulating free DNA (cfDNA) for monitoring EGFR mutations in advanced NSCLC patients: a case report. They present a patient with a long follow-up, where the evolution of EGFR mutations in blood and cerebrospinal fluid mirrored the evolution of the disease, including early response, relapse with emergence of T790M-associated resistance and appearance of brain metastases.
Mutations in the KRAS gene are common in NSCLC, particularly in smokers, and its prognostic and predictive role, both in "true" and "liquid" biopsies is controversial. This controversy, and the current state-of-the-art of KRAS mutation analyses using non-invasive approaches is review by Garzón et al. In their article KRAS mutations in the cfDNA of NSCLC patients they conclude that, although large prospective studies are required to draw definitive answers about the prognostic or predictive value of KRAS mutations in ctDNA, they can already be used to monitor the course of the disease in KRAS mutated patients.
Most of studies on ctDNA and other liquid biopsy-derived materials in lung cancer have been performed in advancedstage patients. The analysis of ctDNA and detection of genetic alterations in early-stage patients presents additional challenges, which are summarized by Pérez-Ramírez et al. in their review Liquid biopsy in early stage lung cancer. Although the low concentration of ctDNA in the blood of early-stage NSCLC patients has hampered its use, the authors are confident that more specific and sensitive techniques will soon enable the use of cfDNA for routine NSCLC diagnosis and monitoring tumor burden, as well as for identifying hidden residual disease after surgery or tumor biomarkers.
Last but not least, Aguado et al. review an area often overshadowed by cfDNA analyses but that has the potential to become the new, great step forward in liquid biopsy. In their article Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients, they offer an overview of how RNA derived from plasma, platelets and CTCs can be used to detect actionable alterations in advanced NSCLC patients, such as fusion involving ALK, ROS1, RET and NTRK genes or MET splicing variants. RNA offers the best available choice for accurate detection of these alterations in blood, which will represent a significant advance for treatment selection at the time of the diagnosis, as well as for monitoring treatment outcome and predicting disease progression in patients carrying these alterations.
